SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
450.50    16.00 (3.68%)
Bid:
449.50
Ask:
451.50
Spread: 2.00 (0.445%)
Market Cap: £221.56m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Q3 Trading Update

3 Nov 2021 07:00

RNS Number : 1247R
Zotefoams PLC
03 November 2021
 

Zotefoams plc

("Zotefoams" or the "Group")

 

Q3 Trading Update

 

3 November 2021 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the third quarter of its financial year ending 31 December 2021 ("Q3 2021").

 

Zotefoams is pleased to report a record third-quarter sales performance, with revenues approximately 11% ahead of Q3 2020 and approximately 35% ahead of Q3 2019. Excluding the significant non-repeating sales of polyolefin foams for personal protective equipment ("PPE") in 2020, Q3 2021 sales increased by approximately 54% compared to Q3 2020.

 

Demand for polyolefin foams has rebounded strongly in most markets, augmented by previously implemented price increases becoming fully effective in the third quarter. Within HPP, sales of footwear products have continued at approximately the same rate as the first half of 2021 but have been negatively impacted by the well-publicised COVID-related shutdown of our customer in Vietnam. Sales of other High-Performance Products were also significantly above the low levels of demand experienced in Q3 2020, with the result that total Q3 2021 HPP sales were up 75% year-on-year.

 

The development and early-stage commercialisation discussions of our ReZorce® mono-material barrier technology continues to meet expectations and we look forward to providing further details of this key initiative with the announcement of the full year results.

 

As previously communicated, the cost base of the business has increased, in part due to the start-up of our Poland facility but also due to commodity polymer price movements, general inflationary cost increases and additional costs incurred in managing current supply chain disruptions and inefficiency. We do not foresee a relaxation in cost pressure in the short to medium term.

 

We have good visibility of confirmed orders for the remainder of 2021 other than for T-FIT® insulation products, where orders are typically not confirmed until shortly before shipment and the project-based environment is more uncertain. Based on our sales forecasts and current foreign exchange rates, and subject to there being no additional material disruption to the business as a result of the ongoing supply chain challenges, the Board expects full-year revenues and profit before tax to be in line with market expectations.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said:

"We have been greatly encouraged by the return of strong underlying demand across most of our industry segments, although continued COVID and supply chain disruption has hampered markets such as automotive, aviation and footwear products. I am pleased that Zotefoams continues to manage this challenging environment of supply chain disruption and cost inflation well, once again demonstrating the resilience and flexibility of our people and our broad customer base. This strong commercial momentum and resilience in operational performance and cash generation gives us confidence to continue to invest for the future in all business units, with ReZorce in particular offering the potential of a very significant opportunity in the years to come"

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

 

 

 

 

 

IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBTBRTMTBMBRB
Date   Source Headline
1st Jun 20174:30 pmRNSDirector/PDMR Shareholding
31st May 20177:00 amRNSDirector/PDMR Shareholding
17th May 20177:00 amRNSTrading Update
12th May 201711:16 amRNSDirector/PDMR Shareholding
12th Apr 20173:34 pmRNSAnnual Report and Accounts and Notice of 2017 AGM
12th Apr 20173:24 pmRNSDirector/PDMR Shareholding
12th Apr 20171:55 pmRNSHolding(s) in Company
10th Apr 20174:02 pmRNSDirector/PDMR Shareholding
6th Apr 20172:27 pmRNSHolding(s) in Company
6th Apr 20172:25 pmRNSHolding(s) in Company
28th Mar 201711:36 amRNSDirector/PDMR Shareholding
27th Mar 201710:16 amRNSHolding(s) in Company
24th Mar 20173:33 pmRNSHolding(s) in Company
23rd Mar 201710:11 amRNSHolding(s) in Company
22nd Mar 20173:28 pmRNSHolding(s) in Company
14th Mar 20175:28 pmRNSDirector/PDMR Shareholding
14th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSCoveris using MuCell® technology
15th Feb 201710:46 amRNSDirector/PDMR Shareholding
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20176:27 pmRNSHolding(s) in Company
12th Jan 20179:36 amRNSDirector/PDMR Shareholding
11th Jan 201710:33 amRNSHolding(s) in Company
10th Jan 20175:34 pmRNSHolding(s) in Company
9th Jan 20177:00 amRNSTrading Update
6th Jan 20177:00 amRNSAppointment of Joint Broker
6th Jan 20177:00 amRNSAcquires full ownership of its joint venture
22nd Dec 20164:35 pmRNSPrice Monitoring Extension
13th Dec 20161:58 pmRNSDirector/PDMR Shareholding
24th Nov 20167:00 amRNSHolding(s) in Company
15th Nov 201612:40 pmRNSDirector/PDMR Shareholding
14th Nov 201610:30 amRNSDirector Declaration
28th Oct 20167:00 amRNSThird Quarter Trading Update
25th Oct 20164:40 pmRNSSecond Price Monitoring Extn
25th Oct 20164:35 pmRNSPrice Monitoring Extension
24th Oct 201612:07 pmRNSSecond Price Monitoring Extn
24th Oct 201612:02 pmRNSPrice Monitoring Extension
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20163:43 pmRNSHolding(s) in Company
18th Oct 201611:56 amRNSDirector/PDMR Shareholding
14th Oct 20164:35 pmRNSPrice Monitoring Extension
13th Oct 20164:35 pmRNSPrice Monitoring Extension
12th Oct 20165:56 pmRNSDirector/PDMR Shareholding
5th Oct 20164:29 pmRNSHolding(s) in Company
14th Sep 201611:16 amRNSDirector/PDMR Shareholding
23rd Aug 20164:40 pmRNSSecond Price Monitoring Extn
23rd Aug 20164:35 pmRNSPrice Monitoring Extension
12th Aug 20167:00 amRNSDirector/PDMR Shareholding
9th Aug 20167:00 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.